Suggested remit - To appraise the clinical and cost effectiveness of dupilumab within its marketing authorisation for treating chronic rhinosinusitis with nasal polyps
Status In progress
Process STA 2018
ID number 1179

Provisional Schedule

Expected publication 14 July 2021

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
16 December 2019 In progress. Referred Augst 2 2019
08 March 2019 (14:00) Scoping workshop (London)
21 January 0019 - 18 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance